by Peter Ciszewski | Oct 1, 2019
Orchard Therapeutics is developing ex vivo autologous hematopoietic stem cell gene therapy for a variety of rare diseases. In this video, Mark Rothera, CEO of the company explains how the regulatory timeline the company has in place for two of its lead...
by Peter Ciszewski | Sep 27, 2019
By Peter Ciszewski; September 27, 2019. The National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology to include a category 1 recommendation for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell...
by Peter Ciszewski | Sep 27, 2019
The U.S. Food and Drug Administration (FDA) has expanded the use Dysport (botulinum toxin type A) to include the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy. The FDA previously approved...
by Peter Ciszewski | Sep 26, 2019
At Ovid Therapeutics, the patients’ input is essential to how they develop medications and how they do business. Leading that mindset is Luke Rosen, Vice President of Patient Engagement & Government Affairs for the company. Rosen, the father of a child with...
by Peter Ciszewski | Sep 25, 2019
The U.S. Food and Drug Administration (FDA) has approved Jynneos, a vaccine designed to prevent smallpox and monkeypox disease. Smallpox afflicted thousands in the early part of the 20th century but was eradicated in the 1980s following an aggressive vaccination...
